Alberto
Esteban Fernández
Hospital Universitario La Paz
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (12)
2024
2023
-
Identifying the patient with heart failure to be treated with vericiguat
Current Medical Research and Opinion, Vol. 39, Núm. 5, pp. 661-669
-
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization
Expert Opinion on Pharmacotherapy, Vol. 24, Núm. 6, pp. 705-713
2022
-
Impact of blood pressure on management and prognosis of patients treated with sacubitril/valsartan
REC: CardioClinics, Vol. 57, Núm. 2, pp. 116-122
-
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care
Expert Opinion on Pharmacotherapy, Vol. 23, Núm. 14, pp. 1589-1599
2021
-
Initiation and titration of sacubitril/valsartan in different types of centers
REC: CardioClinics, Vol. 56, Núm. 2, pp. 92-97
-
Physiopathology, diagnosis, and management of hypomagnesemia in heart failure patients
REC: CardioClinics
2020
-
Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan
Cardiology (Switzerland), Vol. 145, Núm. 5, pp. 275-282
-
Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort
Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 2, pp. 65-69
2019
-
Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort
ESC Heart Failure, Vol. 6, Núm. 6, pp. 1161-1166
-
Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan
Cardiology (Switzerland), Vol. 142, Núm. 2, pp. 73-78
2018
-
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial
Journal of cardiovascular pharmacology, Vol. 72, Núm. 2, pp. 112-116